Go to: content | top | bottom | search
You are hereUNIL > Quantitative Mass Spectrometry Facility > Other > Grant Proposals > Competencies of Applicants

Competencies of Collaborators and Partners

Competencies of the Applicants and Partners:

Find below, applicants' and partners' articles in the Analytical Chemistry, Drug Metabolism, Molecular Biology and Biochemistry, Access to Clinical Samples, In Silico Modelization.

Analytical Chemistry (B. Rochat):

Rochat B, Zoete V, Grosdidier A, von Grünigen S, Marull M and Michielin O. In Vitro Biotransformation of Imatinib by the Tumor Expressed CYP1A1 and CYP1B1. Biopharm Drug Dispos. 2008;29:103-18.

Rochat B, Fayet F, Widmer N, Lahrichi S, Pesse B, Décosterd L, and Biollaz J. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using Liquid chromatography - mass spectrometry. J Mass Spectrom 2008;43:736-52.

Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1982-1996.

Drug Metabolism (B. Rochat): 

Rochat B. Role of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in the Intratumoral Disposition of Anti-Cancer Agents. Curr Cancer Drug Target. Curr Cancer Drug Targets. 2009;9:652-74.

Rochat B, Zoete V, Grosdidier A, von Grünigen S, Marull M and Michielin O. In Vitro Biotransformation of Imatinib by the Tumor Expressed CYP1A1 and CYP1B1. Biopharm Drug Dispos. 2008;29:103-18.

Rochat B, Murray GI, Figg WD and McLeod HL (2001). Role of CYP 1B1 in biotransformation of anticancer agents : mechanism for tumor-specific drug inactivation? J Pharmacol and Exp Ther; 296:537-541.

Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet.; 2005: 44 (4): 349-66. Review.

Molecular Biology and Biochemistry. Drug Metabolism (I. de Waziers, X. Decleves):

Narjoz C, Marisa L, Imbeaud S, Paris A, Delacroix H, Beaune P, de Waziers I. Genomic consequences of cytochrome P450 2C9 overexpression in human hepatoma cells. Chem Res Toxicol. 2009;22:779-87.

Nguyen TA, Tychopoulos M, Bichat F, Zimmermann C, Flinois JP, Diry M, Ahlberg E, Delaforge M, Corcos L, Beaune P, Dansette P, André F, de Waziers I. Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo. Mol Pharmacol. 2008;73:1122-33.

Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics. 2007;17:731-42.

Declèves X, Bihorel S, Debray M, Yousif S, Camenisch G, Scherrmann JM. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacol Res. 2008;57:214-22

Please, additional information at the following website:  the University Paris 5  for I. de Waziers and X. Decleves.

Access to Clinical Samples and Oncology (D. Berthold, A. Gronchi, O. Michielin, M. Montemurroand, D. Rimoldi and D. Speiser ):

Montemurro M, Schöffski P,  Reichardt P, Gelderblom H, Schütte J, Hartmann JT, von Moos R, Seddon B, Joensuu H, Wendtner CM, Weber E, Grünwald V, Roth A, Leyvraz S. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009; 45:2293-7.

Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009; 27:439-45.

Montemurro M, Achtari L, Röth A, Halkic N, Luthi F, Ozsahin M, Denys A, Bauer J, Demartines N, Leyvraz S. Systemic treatment of metastatic colorectal cancer. Rev Med Suisse. 2008; 4:1254-7. Review. French.

Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ. Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol. 2008;31:182-187.

De Dosso S, Berthold DR. Docetaxel in the management of prostate cancer: current standard of care and future directions. Expert Opin Pharmacother. 2008;9:1969-1979.

Michielin O. Application of molecular modeling to new therapeutic cancer approaches. Bull Cancer. 2007;94:763-8. Review.
Stupp R, Pica A, Mirimanoff RO, Michielin O. A practical guide for the management of gliomas. Bull Cancer. 2007;94:817-22.

Conca E, Negri T, Gronchi A, Fumagalli E, Tamborini E, Pavan GM, Fermeglia M, Pierotti MA, Pricl S, Pilotti S. Activate and resist: L576P-KIT in GIST. Mol Cancer Ther. 2009. in press

Thomas DM, O'Sullivan B, Gronchi A. Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. Expert Rev Anticancer Ther. 2009;9:1145-57.

Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, Schöffski P.Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol. 2009;36:290-301.

Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Fiore M, Hohenberger P, Gronchi A. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol. 2009 in press.

Please, additional information at the following websites: the CHUV for Drs. O. Michielin, M. Montemurro and D. Berthold, the Istituto Nationale dei Tumori for Dr. A. Gronchi and the Ludwig Institute for cancer research for D. Rimoldi and D. Speiser.

In Silico Modelization (Bioinformatics (F. Andre, T. Buclin, G. Ecker, O. Michielin):

Röhrig UF, Grosdidier A, Zoete V, Michielin O. Docking to heme proteins. J Comput Chem. 2009; 30:2305-15.

Zoete V, Grosdidier A, Michielin O.Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med. 2009;13:238-48.

Grosdidier A, Zoete V, Michielin O. Blind docking of 260 protein-ligand complexes with EADock 2.0. J Comput Chem. 2009; 30:2021-30.

Grosdidier A, Zoete V, Michielin O. EADock: docking of small molecules into protein active sites with a multiobjective evolutionary optimization. Proteins. 2007; 67:1010-25.

Demel MA, Schwaha R, Krämer O, Ettmayer P, Haaksma EE, Ecker GF. In silico prediction of substrate properties for ABC-multidrug transporters. Expert Opin Drug Metab Toxicol. 2008;4:1167-80. Review.

Ecker GF, Stockner T, Chiba P. Computational models for prediction of interactions with ABC-transporters. Drug Discov Today. 2008; 13:311-7. Review.

Lafite P, André F, Zeldin DC, Dansette PM, Mansuy D. Unusual regioselectivity and active site topology of human cytochrome P450 2J2. Biochemistry. 2007; 46: 10237-47.

Meslamani JE, André F, Petitjean M. Assessing the geometric diversity of cytochrome P450 ligand conformers by hierarchical clustering with a stop criterion. J Chem Inf Model. 2009; 49: 330-7.

Widmer N, Decosterd, LA, Csjaka C, Leyvraz S, Duchosal, MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz, J, Buclin T. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol. 2006;62:97-112.

Perrottet N, Csajka C, Pascual M, Manuel O, Lamoth F, Meylan P, Aubert JD, Venetz JP, Soccal P, Decosterd LA, Biollaz J, Buclin T. Population pharmacokinetics of ganciclovir in solid organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother. 2009; 53:3017-23.

Please, additional information at the following website: the SIB for Dr.  O. Michielin, the CEA for Dr. F. André , the Wien University for Dr. G. Ecker and the CHUV for Th. Buclin and C. Csajka.

youtube youtube 
CH-1015 Lausanne  - Switzerland  -  Tel. +41 21 314 41 58  -  Fax +41 21 314 41 65
Swiss University